JP2005505545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505545A5 JP2005505545A5 JP2003524516A JP2003524516A JP2005505545A5 JP 2005505545 A5 JP2005505545 A5 JP 2005505545A5 JP 2003524516 A JP2003524516 A JP 2003524516A JP 2003524516 A JP2003524516 A JP 2003524516A JP 2005505545 A5 JP2005505545 A5 JP 2005505545A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tyrphostin
- effective amount
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010007554 Cardiac failure Diseases 0.000 claims 4
- 206010019280 Heart failure Diseases 0.000 claims 4
- 101700016050 JAK2 Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 210000002966 Serum Anatomy 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- TUCIOBMMDDOEMM-RIYZIHGNSA-N (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
Claims (17)
- 高血圧のおそれのある哺乳類における高血圧を減少させる医薬組成物であって、有効量の選択的Jak2阻害剤を含むことを特徴とする医薬組成物。
- 前記Jak2阻害剤が、チルホスチンである請求項１に記載の医薬組成物。
- 前記チルホスチンが、チルホスチンAG490である請求項２に記載の医薬組成物。
- 前記哺乳類が、ヒトである請求項１に記載の医薬組成物。
- 全身的に投与される請求項１に記載の医薬組成物。
- 前記高血圧に由来する損傷が発生する前に投与される請求項１に記載の医薬組成物。
- 前記有効量が、約0.05μMから約10μMの間の血清レベルを生じる請求項１に記載の医薬組成物。
- 前記有効量が、約１μMから約５μMの間の血清レベルを生じる請求項７に記載の医薬組成物。
- 心不全のおそれのある哺乳類において心不全を減少させる医薬組成物であって、有効量の選択的Jak2阻害剤を含むことを特徴とする医薬組成物。
- 前記Jak2阻害剤が、チルホスチンである請求項９に記載の医薬組成物。
- 前記チルホスチンが、チルホスチンAG490である請求項10に記載の医薬組成物。
- 前記哺乳類が、ヒトである請求項９に記載の医薬組成物。
- 心不全が発生する前に投与される請求項９に記載の医薬組成物。
- 更なる損傷を予防するために心不全が発生した後で投与される請求項９に記載の医薬組成物。
- 全身的に投与される請求項９に記載の医薬組成物。
- 前記有効量が、約0.05μMから約10μMの間の血清レベルを生じる量である請求項９に記載の医薬組成物。
- 前記有効量が、約１μMから約５μMの間の血清レベルを生じる量である請求項16に記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/945,192 US6433018B1 (en) | 2001-08-31 | 2001-08-31 | Method for reducing hypertrophy and ischemia |
| PCT/US2002/023444 WO2003020202A2 (en) | 2001-08-31 | 2002-07-23 | Method for reducing hypertension and heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010180146A Division JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505545A JP2005505545A (ja) | 2005-02-24 |
| JP2005505545A5 true JP2005505545A5 (ja) | 2006-01-05 |
Family
ID=25482762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524516A Pending JP2005505545A (ja) | 2001-08-31 | 2002-07-23 | 高血圧及び心不全を減少させる方法 |
| JP2010180146A Pending JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010180146A Pending JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6433018B1 (ja) |
| EP (1) | EP1427401A4 (ja) |
| JP (2) | JP2005505545A (ja) |
| KR (1) | KR20040050894A (ja) |
| AU (1) | AU2002313700B2 (ja) |
| BR (1) | BR0212252A (ja) |
| CA (1) | CA2458798C (ja) |
| MX (1) | MXPA04001913A (ja) |
| NZ (1) | NZ531693A (ja) |
| WO (1) | WO2003020202A2 (ja) |
| ZA (1) | ZA200402540B (ja) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20050038450A1 (en) * | 2003-06-03 | 2005-02-17 | Ping Hu | Methods and apparatus for minimally invasive transverse aortic banding |
| NZ545270A (en) * | 2003-07-30 | 2010-04-30 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| US20050130893A1 (en) * | 2003-09-30 | 2005-06-16 | Joan Smith-Sonneborn | Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure |
| EP2487156B1 (en) | 2003-12-11 | 2014-07-16 | Board Of Regents The University Of Texas System | Compounds for treatment of cell proliferative diseases |
| US20100113481A1 (en) * | 2003-12-17 | 2010-05-06 | Alcon Research, Ltd. | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| TWI398261B (zh) * | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
| WO2006044694A2 (en) * | 2004-10-15 | 2006-04-27 | Palo Alto Investors | Methods and compositions for treating a disease condition in a subject |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| KR101312225B1 (ko) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Ｊａｋ 경로의 억제를 위한 조성물 및 방법 |
| KR101499594B1 (ko) | 2005-11-16 | 2015-03-09 | 씨티아이 바이오파마 코포레이션 | 산소가 결합된 피리미딘 유도체 |
| US10517876B2 (en) | 2005-11-16 | 2019-12-31 | Cti Biopharma Corp. | Oxygen linked pyrimidine derivatives |
| AU2007205982A1 (en) * | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Xenohormesis based compositions and methods |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2007101232A2 (en) * | 2006-02-28 | 2007-09-07 | Cytopia Research Pty, Ltd. | Inhibition of jak2 as a treatment of pulmonary arterial hypertension |
| JP5654233B2 (ja) * | 2006-03-31 | 2015-01-14 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 経口で生物学的に利用できるコーヒー酸関連抗癌剤 |
| KR20150043565A (ko) | 2007-03-12 | 2015-04-22 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| AU2009268841B2 (en) | 2008-07-08 | 2014-02-06 | Board Of Regents, The University Of Texas System | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS) |
| ES2536558T3 (es) | 2008-12-11 | 2015-05-26 | Cti Biopharma Corp. | Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno |
| CN102470135A (zh) * | 2009-07-28 | 2012-05-23 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| JP5275966B2 (ja) * | 2009-12-21 | 2013-08-28 | パナソニック株式会社 | 繊維ボードの製造方法 |
| WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| IN2014CN04065A (ja) | 2011-11-23 | 2015-09-04 | Portola Pharm Inc | |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| CA2012634A1 (en) * | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| US6255296B1 (en) | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| US6358954B1 (en) * | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| DE602006000402T8 (de) * | 2006-06-02 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung. |
-
2001
- 2001-08-31 US US09/945,192 patent/US6433018B1/en not_active Expired - Lifetime
-
2002
- 2002-07-23 EP EP02753409A patent/EP1427401A4/en not_active Withdrawn
- 2002-07-23 KR KR10-2004-7003111A patent/KR20040050894A/ko not_active Application Discontinuation
- 2002-07-23 NZ NZ531693A patent/NZ531693A/en not_active IP Right Cessation
- 2002-07-23 AU AU2002313700A patent/AU2002313700B2/en not_active Ceased
- 2002-07-23 BR BR0212252-9A patent/BR0212252A/pt not_active IP Right Cessation
- 2002-07-23 JP JP2003524516A patent/JP2005505545A/ja active Pending
- 2002-07-23 CA CA2458798A patent/CA2458798C/en not_active Expired - Fee Related
- 2002-07-23 MX MXPA04001913A patent/MXPA04001913A/es active IP Right Grant
- 2002-07-23 US US10/488,279 patent/US7235588B2/en not_active Expired - Lifetime
- 2002-07-23 WO PCT/US2002/023444 patent/WO2003020202A2/en active IP Right Grant
-
2004
- 2004-03-31 ZA ZA2004/02540A patent/ZA200402540B/en unknown
-
2010
- 2010-08-11 JP JP2010180146A patent/JP2010285455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505545A5 (ja) | ||
| MX9706785A (es) | Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato. | |
| Haas et al. | critical care issues for the nephrologist: current diagnosis and management of Hypertensive Emergency | |
| JP2007512371A5 (ja) | ||
| JP2004538303A5 (ja) | ||
| ECSP088422A (es) | Composiciones farmacéuticas sólidas que contienen pregabalina | |
| AR054833A1 (es) | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina | |
| EP2283826A3 (en) | Galenic formulations of organic compounds | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| CA2457361A1 (en) | Opioid agonist formulations with releasable and sequestered antagonist | |
| JP2005532372A5 (ja) | ||
| WO2003020202A3 (en) | Method for reducing hypertension and heart failure | |
| EP1107747A1 (en) | Therapies for treating pulmonary diseases | |
| HRP20130424T4 (hr) | Postupci upotrebe sastava aminopiridina s odgođenim oslobađanjem | |
| ATE486840T1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
| WO2003039519A3 (es) | Forma de dosificación de liberación controlada dual | |
| DK1553927T3 (da) | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger | |
| JP2005512995A5 (ja) | ||
| WO2003018061A1 (fr) | Medicaments contenant un inhibiteur de la chymase et un inhibiteur de l'ace comme principes actifs | |
| RU2016133305A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| DE50212267D1 (de) | Transdermales therapeutisches system für die verabreichung carboxylgruppenhaltiger, nichtsteroidaler antiphlogistika, sowie verfahren zu seiner herstellung | |
| EP3078386A3 (en) | Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor | |
| WO2005121329A3 (en) | Method for ameliorating an inflammatory skin condition | |
| WO2001082919A3 (en) | Methods of and compounds for inhibiting calpains | |
| DE602004006009D1 (de) | Pellets mit venlafaxin-hydrochlorid |